Gilead Sciences To Acquire Immunomedics
September 13, 2020 at 16:51 PM EDT
Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share. The transaction values Immunomedics at approximately $21 billion.
